Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy
| dc.contributor.author | Newman, M. J. | |
| dc.contributor.author | Wilson, C. C. | |
| dc.contributor.author | Livingston, B. D. | |
| dc.contributor.author | MaWhinney, S. | |
| dc.contributor.author | Forster, J.E. | |
| dc.contributor.author | Scott, J. | |
| dc.contributor.author | Schooley, R. T. | |
| dc.contributor.author | Benson, C.A | |
| dc.date.accessioned | 2012-04-30T13:57:17Z | |
| dc.date.accessioned | 2017-10-19T12:10:26Z | |
| dc.date.available | 2012-04-30T13:57:17Z | |
| dc.date.available | 2017-10-19T12:10:26Z | |
| dc.date.issued | 2008 | |
| dc.description.abstract | A DNA vaccine encoding sequence-conserved human immunodeficiency virus type 1 (HIV-1)-derived cytotoxic T-lymphocyte (CTL) epitopes from multiple HIV-1 gene products (designated EP HIV-1090) was evaluated in a placebo-controlled, dose escalation phase 1 clinical trial of HIV-1-infected subjects receiving potent combination antiretroviral therapy. Patients received four intramuscular immunizations with EP HIV-1090 over a 4-month period at one of four doses (0.5, 1.0, 2.0, or 4.0 mg) or received a placebo. The vaccine was determined to be safe and well tolerated at all doses tested. CTL responses were measured from cryopreserved peripheral blood mononuclear cells using gamma interferon enzyme-linked immunospot assays, with and without in vitro peptide stimulation (IVS). Responses to one or more vaccine epitopes were detected throughout the course of vaccination in 37.5% (12/32) and 47% (15/32) of vaccine recipients measured without and with IVS, respectively, indicating possible vaccine-induced priming of epitope-specific T cells. However, differences in rates of response to HIV-1 epitopes between vaccine and placebo recipients did not achieve statistical significance. The HIV-1 epitope-specific CTL responses measured in the peripheral blood after vaccination were often low level and short-lived, and therefore, alternative immunization schedules, routes of delivery, or vaccine formulations may be required to increase vaccine potency. | en_US |
| dc.identifier.uri | http://197.255.68.203/handle/123456789/837 | |
| dc.language.iso | en | en_US |
| dc.publisher | Clin. Vaccine Immunol.15(6): 986-94. | en_US |
| dc.title | Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy | en_US |
| dc.type | Article | en_US |